Q3 2025 Management View Stéphane Bancel, CEO, reported third quarter revenue of $1 billion, driven by sales of fully approved vaccines including Spikevax, mNEXSPIKE, and mRESVIA, and announced a net ...

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO Stéphane Bancel had the unenviable task of trying to put a positive spin ...

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter. He will remain chief executive of the biotech company. Moderna president ...

Moderna on Thursday said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine ...

Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, a person close to the matter told Fierce Pharma. The layoffs are hitting ...

“Thanks to your company’s work and Pfizer too, you guys saved the world,” Ted Tenthhoff, senior biotech analyst at Piper Sandler, told Stéphane Bancel, CEO of Moderna, at the former’s 36 th Annual ...

Oct 20 (Reuters) - Moderna Inc (MRNA.O), opens new tab Chief Executive Officer Stéphane Bancel expects interim results from its COVID-19 vaccine trial in November and that the U.S government could ...